YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, announced on Thursday the appointment of Anne Prener to its Board of Directors, effective from July 1, 2026. Prener currently serves as a Senior Innov…
Exelixis, Inc. EXEL recently announced that it has initiated the dose-escalation stage of the first-in-human phase I study of investigational candidate XL114. XL114 is a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 compl…
NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Kaleido Biosciences, Inc. (“Kaleido Biosciences” or the “Company”) (Nasdaq: KLDO). On September…
Kaleido Biosciences Inc (NASDAQ: KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all operations. The Company expects to file a Form 25 with the Securities and Exchange Commissio…
Novartis NVS recently announced that the European Commission (“EC”) has approved a label expansion of its ophthalmology drug Beovu (brolucizumab). The EC approved Beovu for the treatment of visual impairment due to diabetic macular edema (…
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.…
Roche RHHBY announced disappointing results from the phase III SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC). The study did not meet its co-primary endpoint of progression-free survival. SKYSCRAPER-02 is a global…
Bristol Myers Squibb BMY announced that the European Medicines Agency (“EMA”) has validated its type II variation application for Opdivo (nivolumab) in combination with chemotherapy. The application sought approval for the neoadjuvant trea…
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency has adopted a positive opinion recommending the approval of Jakavi (ruxolitinib), an oral inhibitor of the JAK 1 and J…
Bristol Myers Squibb BMY announced that the FDA has extended the review of the supplemental biologics license application (sBLA) for Reblozy (luspatercept-aamt). The sBLA is seeking approval for the treatment of anemia in adults with non-t…
Shares of Bristol Myers BMY have jumped 16.1% in the year so far against the industry’s decline of 13.8%. Performance of key drugs and encouraging pipeline progress have impressed investors. Zacks Investment Research Image Source: Zacks In…
Rezolute, Inc. RZLT announced positive data from the phase IIb RIZE study, which is evaluating its lead pipeline candidate RZ358 for the treatment of congenital hyperinsulinism (HI), the most common cause of recurrent hypoglycemia in child…
Shares of ORIC Pharmaceuticals, Inc. ORIC tanked 28.7% after the company announced the discontinuation of pipeline candidate ORIC-101 concurrent with fourth-quarter results. The candidate was being studied in combination with nab-paclitaxe…
Bristol Myers Squibb BMY announced that the FDA has approved a new, first-in-class, fixed-dose combination of PD-1 inhibitor Opdivo (nivolumab) and relatlimab (novel LAG-3-blocking antibody) administered as a single intravenous infusion fo…
Radius Health Inc. BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley ha…
BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as…
Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items. This…
Shares of AnaptysBio, Inc. ANAB were down 10.5% in after-hours trading on Monday after it announced top-line data from the phase II ACORN study, which evaluated its pipeline candidate, imsidolimab, for the treatment of moderate-to-severe a…
Acadia Pharmaceuticals Inc. ACAD announced that it has received the action date from the FDA related to its resubmitted supplemental New Drug Application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheim…
Bristol Myers Squibb BMY announced that the FDA has approved the label expansion of its immuno-oncology drug Opdivo (nivolumab). The regulatory body approved Opdivo 360 mg (injection for intravenous use) in combination with platinum-double…
Horizon Therapeutics plc HZNP reported fourth-quarter 2021 adjusted earnings of $1.41 per share, which beat the Zacks Consensus Estimate of $1.27. The company reported adjusted earnings of $1.17 in the year-ago quarter. Quarterly sales of…
Acadia Pharmaceuticals Inc. ACAD reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. In the year-ago quarter, the company incurred a loss of 42 cents per share. Total re…
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appoint…
Global Blood Therapeutics, Inc. GBT incurred a loss of $1.36 per share in fourth-quarter 2021, wider than the Zacks Consensus Estimate of a loss of $1.14. In the year-ago quarter, the company had reported a loss of $1.00 per share. The com…
Wall Street expects a year-over-year decline in earnings on lower revenues when Kaleido Biosciences, Inc. (KLDO) reports results for the quarter ended December 2021. While this widely-known consensus outlook is important in gauging the com…
Novavax, Inc. NVAX is scheduled to report fourth-quarter 2021 results on Feb 28, after market close. The company’s surprise record has been dismal so far, as its earnings missed expectations in each of the four trailing quarters, with the…
We expect Perrigo Company plc PRGO to beat expectations when it reports fourth-quarter and full-year results on Mar 1. In the last-reported quarter, the company delivered a negative earnings surprise of 30.77%. Perrigo’s earnings performan…
Blueprint Medicines Corporation BPMC incurred an adjusted loss of 99 cents per share (excluding a one-time payment of $260 million incurred for the acquisition of Lengo Therapeutics) for fourth-quarter 2021, wider than the Zacks Consensus…
In this article, we discuss 10 cheap pharmaceutical stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 Cheap Pharmaceutical Stocks For 2022. The pharma industry is in the midst of a fundamental tra…
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and envi…
Kaleido Biosciences, Inc. (KLDO) has been on a downward spiral lately with significant selling pressure. After declining 33.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territor…
Kaleido Biosciences Inc (NASDAQ: KLDO) halted work on a planned phase 2 trial in chronic obstructive pulmonary disease (COPD) and terminated its agreement with the COPD Foundation to realign resources. The Company had announced the COPD ag…
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively t…
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively t…
Kaleido Biosciences, Inc. KLDO has been struggling lately, but the selling pressure may be coming to an end soon. That is because KLDO recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. What is a Hamme…
Investment company Fidelity Salem Street Trust (Current Portfolio) buys AMC Entertainment Holdings Inc, E2open Parent Holdings Inc, Coursera Inc, Option Care Health Inc, Brookfield Infrastructure Corp, sells , Sykes Enterprises Inc, Macqua…